Englander Israel A's Form 4 filing
Faeth Therapeutics, Inc. (FTH) · filed May 15, 2026
- Accession no.
- 0001104659-26-062605
- Filed
- May 15, 2026, 4:22 PM ET
- Trade date
- Mar 31-Apr 1, 2026
- Filing delay
- 45 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 17 non-derivative transactions and 0 derivative transactions. Open-market purchases total $382.1K. Open-market sales total $76.9K. It was filed 45 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Englander Israel ACIK 0001017456 | 10% Owner |
| Millennium Management LLCCIK 0001273087 | 10% Owner |
| Millennium Group Management LLCCIK 0001446830 | 10% Owner |
| Ics Opportunities II LLCCIK 0001783647 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +616 | $24.69 | +$15,206.39 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +1,770 | $25.32 | +$44,817.99 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +1,048 | $26.73 | +$28,008.74 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +17 | $27.78 | +$472.32 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +186 | $30.48 | +$5,668.42 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +1,957 | $31.45 | +$61,550 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +411 | $32.60 | +$13,397.04 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −191 | $24.28 | −$4,638.3 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −1,251 | $25.17 | −$31,484.67 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −57 | $27.11 | −$1,545.54 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −5 | $28.41 | −$142.03 | 146,657 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −87 | $31.52 | −$2,742.24 | 146,657 | Indirect | |
| Apr 1, 2026 | Common Stock | PPurchaseAcquired | +1,161 | $31.53 | +$36,607.37 | 147,731 | Indirect | |
| Apr 1, 2026 | Common Stock | PPurchaseAcquired | +1,613 | $34.59 | +$55,787.7 | 147,731 | Indirect | |
| Apr 1, 2026 | Common Stock | PPurchaseAcquired | +3,401 | $35.46 | +$120,583.82 | 147,731 | Indirect | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −1,104 | $31.52 | −$34,798.08 | 147,731 | Indirect | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −46 | $34.75 | −$1,598.33 | 147,731 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.